Breaking News Instant updates and real-time market news.

NKTR

Nektar

$39.99

0.98 (2.51%)

, PFE

Pfizer

$43.52

0.6 (1.40%)

08:36
11/06/18
11/06
08:36
11/06/18
08:36

Nektar enters into oncology clinical collaboration with Pfizer

Nektar Therapeutics (NKTR) announced that it has entered into an oncology clinical collaboration with Pfizer (PFE) to evaluate several combination regimens in multiple cancer settings, including metastatic castration-resistant prostate cancer, or mCRPC, and squamous cell carcinoma of the head and neck, or SCCHN. The collaboration will evaluate Nektar's lead immuno-oncology candidate, the CD122-biased agonist NKTR-214 with avelumab, a human anti-PD-L1 antibody in development by Merck KGaA, Darmstadt, Germany, and Pfizer; talazoparib, a poly polymerase inhibitor developed by Pfizer; or enzalutamide, an androgen receptor inhibitor in development by Pfizer and Astellas Pharma. Under the new collaboration, Pfizer will initiate a Phase 1b/2 clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214. Nektar, Pfizer and their respective partners will each maintain global commercial rights to their respective medicines.

NKTR

Nektar

$39.99

0.98 (2.51%)

PFE

Pfizer

$43.52

0.6 (1.40%)

  • 07

    Nov

  • 07

    Nov

  • 10

    Nov

  • 12

    Nov

  • 27

    Nov

NKTR Nektar
$39.99

0.98 (2.51%)

08/08/18
PIPR
08/08/18
NO CHANGE
Target $125
PIPR
Overweight
Nektar offered more 'granularity' on PIVOT data timing, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $125 price target on Nektar after its Q2 earnings beat, saying the management has also offered more detail on the company's data release plans. The analyst sees the 1L melanoma cohort readout coming before the end of 2018, followed by RCC and bladder cancer data likely in the first half of 2019 and other tumor types later next year. Van Buren adds that these disclosures should hopefully add to the company's understanding about the efficacy of 214+nivo combination therapy.
08/09/18
MZHO
08/09/18
NO CHANGE
Target $103
MZHO
Buy
Nektar to report additional data in coming months, says Mizuho
Mizuho analyst Difei Yang reiterates a Buy rating on Nektar Therapeutics with a $103 price target following last night's Q2 results. Data readouts of NKTR-214 remain the main catalyst for the shares, Yang tells investors in a research note. She points out that management expects to present data at a number of conferences in the coming months, including melanoma data at the Society for Immunotherapy of Cancer on November 7-11. While details on additional data in other indications "were sparse," data should be announced over the coming six-to-eight months, Yang contends.
10/22/18
HCWC
10/22/18
NO CHANGE
Target $54
HCWC
Neutral
Roche data should concern Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes Roche's (RHHBY) preliminary data of RO6875281, a fibroblast activation protein targeted interleukin-2 variant, should concern the bulls of Nektar Therapeutics (NKTR). The 11% and 20% overall response rate for single agent RO6875281 in squamous cell head and neck cancer and melanoma is compelling, Chattopadhyay tells investors in a research note. Nektar's NKTR-214 had no monotherapy activity, and the early promise in combination with Opdivo "has faded potentially due to its limited PK profile," the analyst adds. In addition, Chattopadhyay believes the monotherapy activity with pegilodecakin, a pegylated IL-10 being developed by Eli Lily (LLY), further complicates the competitive landscape for NKTR-214. He believes the second generation of "not alpha" IL-2, which is poised to enter the clinic during 2019, could further "upend" NKTR-214 and might compel Nektar's partner Bristol-Myers Squibb (BMY) to "re-evaluate the aggressive development strategy that was outlined earlier this year." The analyst keeps a Neutral rating on Nektar with a $54 price target.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $47
HCWC
Neutral
Nektar price target lowered to $47 from $54 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Nektar Therapeuticsless than (NKTR) to $47 and keeps a Neutral rating on the shares. While the Phase 3 trial of Opdivo plus NKTR-214 is welcome news, the company faces a crowded frontline renal cell carcinoma treatment landscape and stiff commercial hurdles, Chattopadhyay tells investors in a research note. He believes that unless the NKTR-214 plus Opdivo combination is meaningfully superior to the Opdivo and Yervoy combination, Bristol-Myers (BMY) "may not be willing to muscle the commercial launch, given the cannibalization of its existing franchise."
PFE Pfizer
$43.52

0.6 (1.40%)

11/01/18
BMOC
11/01/18
DOWNGRADE
BMOC
Market Perform
Pfizer downgraded to Market Perform from Outperform at BMO Capital
11/01/18
BMOC
11/01/18
DOWNGRADE
Target $46
BMOC
Market Perform
Pfizer downgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital analyst Alex Arfaei downgraded Pfizer to Market Perform from Outperform and lowered his price target to $46 from $47. The analyst maintains a positive view on the company longer-term but sees valuation at current levels reflecting its risk-reward profile. Arfaei points to potential headwinds facing Pfizer that include immuno-oncology R&D execution, along with disappointing sales from Prevnar, Ibrance, Xtandi, and Xeljanz. The analyst also believes that the positives of margin expansion and the prospects of Pfizer's pipeline assets like Tafamidis and Tanezumab are accounted by its stock price.
11/01/18
11/01/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Market Perform from Outperform at BMO Capital with analyst Alex Arfaei saying he maintains a positive view on the company longer-term but sees valuation at current levels reflecting its risk-reward profile. 2. Encana (ECA) downgraded to Underperformer from Neutral at CIBC. 3. New Oriental Education (EDU) downgraded to Hold from Buy at Deutsche Bank with analyst Tallan Zhou saying he expects "lingering margin pressure" following Q1 results. 4. Autoliv (ALV) downgraded to Neutral from Buy at Longbow with analyst Anthony Deem saying he sees the company's revenue growth being "very solid" through 2020 in mid-to-high single digit percentage territory, but he is less confident in positive operating leverage due to incremental cost overruns associated with new launches. 5. Aegion (AEGN) downgraded to Hold from Buy at Canaccord with analyst Chip Moore saying the company is a well positioned pipeline infrastructure play that is poised to benefit from attractive secular drivers longer-term, but the risk/reward is balanced at current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/06/18
SBSH
11/06/18
INITIATION
Target $25
SBSH
Sell
Solid Biosciences initiated with a Sell at Citi
Citi analyst Joel Beatty started Solid Biosciences (SLDB) with a Sell rating and $25 price target. The analyst believes the gene therapy agents in clinical development for Duchenne muscular dystrophy by Sarepta (SRPT) and Pfizer (PFE) will leave little market share to Solid Bio's SGT-001. The analyst forecasts Sarepta capturing the largest share of the DMD gene therapy market, followed by Pfizer, and then Solid.

TODAY'S FREE FLY STORIES

IRWD

Ironwood

$11.96

0.32 (2.75%)

06:01
11/19/18
11/19
06:01
11/19/18
06:01
Recommendations
Ironwood analyst commentary  »

Ironwood price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:00
11/19/18
11/19
06:00
11/19/18
06:00
General news
FX Action: USD-JPY has retained a heavy tone »

FX Action: USD-JPY has…

YETI

Yeti

$16.99

0.1 (0.59%)

05:59
11/19/18
11/19
05:59
11/19/18
05:59
Initiation
Yeti initiated  »

Yeti initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RHHBY

Roche

$0.00

(0.00%)

05:57
11/19/18
11/19
05:57
11/19/18
05:57
Downgrade
Roche rating change  »

Roche downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 24

    Dec

NVS

Novartis

$87.74

0.52 (0.60%)

05:56
11/19/18
11/19
05:56
11/19/18
05:56
Upgrade
Novartis rating change  »

Novartis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

TI

Telecom Italia

$6.02

0.12 (2.03%)

05:53
11/19/18
11/19
05:53
11/19/18
05:53
Hot Stocks
Telecom Italia appoints Luigi Gubitosi as CEO »

On Sunday, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STNE

StoneCo

$25.31

0.69 (2.80%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Initiation
StoneCo initiated  »

StoneCo initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

05:51
11/19/18
11/19
05:51
11/19/18
05:51
Downgrade
AstraZeneca rating change  »

AstraZeneca downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 03

    Dec

JPDYY

Japan Display

$0.00

(0.00%)

05:49
11/19/18
11/19
05:49
11/19/18
05:49
Downgrade
Japan Display rating change  »

Japan Display downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTRX

Retrophin

$25.17

0.44 (1.78%)

05:46
11/19/18
11/19
05:46
11/19/18
05:46
Initiation
Retrophin initiated  »

Retrophin initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

YETI

Yeti

$16.99

0.1 (0.59%)

05:43
11/19/18
11/19
05:43
11/19/18
05:43
Initiation
Yeti initiated  »

Yeti initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

EOLS

Evolus

$14.75

0.06 (0.41%)

05:40
11/19/18
11/19
05:40
11/19/18
05:40
Hot Stocks
Evolus announces conditional acceptance from FDA for Jeuveau brand name »

Evolus announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

MNK

Mallinckrodt

$30.85

-0.58 (-1.85%)

05:39
11/19/18
11/19
05:39
11/19/18
05:39
Upgrade
Mallinckrodt rating change  »

Mallinckrodt upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

CPAC

Cementos Pacasmayo

$9.98

(0.00%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Cementos Pacasmayo rating change  »

Cementos Pacasmayo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VKTX

Viking Therapeutics

$11.65

0.27 (2.37%)

05:38
11/19/18
11/19
05:38
11/19/18
05:38
Upgrade
Viking Therapeutics rating change  »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JD

JD.com

$23.04

-1.18 (-4.87%)

05:37
11/19/18
11/19
05:37
11/19/18
05:37
Earnings
Breaking Earnings news story on JD.com »

JD.com sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

MDGL

Madrigal Pharmaceuticals

$129.47

-3.36 (-2.53%)

05:36
11/19/18
11/19
05:36
11/19/18
05:36
Downgrade
Madrigal Pharmaceuticals rating change  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

JD

JD.com

$23.04

-1.18 (-4.87%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Earnings
JD.com reports Q3 EPS 15c, consensus 10c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMH

American Homes 4 Rent

$19.83

-0.04 (-0.20%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Downgrade
American Homes 4 Rent rating change  »

American Homes 4 Rent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BB

BlackBerry

$8.97

0.12 (1.36%)

05:35
11/19/18
11/19
05:35
11/19/18
05:35
Upgrade
BlackBerry rating change  »

BlackBerry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMAX

RE/MAX Holdings

$30.26

-0.23 (-0.75%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RE/MAX Holdings rating change  »

RE/MAX Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

RNG

RingCentral

$76.41

-0.54 (-0.70%)

05:34
11/19/18
11/19
05:34
11/19/18
05:34
Upgrade
RingCentral rating change  »

RingCentral upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Upgrade
TD Ameritrade rating change  »

TD Ameritrade upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$46.97

-0.35 (-0.74%)

05:33
11/19/18
11/19
05:33
11/19/18
05:33
Downgrade
Charles Schwab rating change  »

Charles Schwab downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

05:32
11/19/18
11/19
05:32
11/19/18
05:32
Hot Stocks
Nissan finds 'significant acts of misconduct' by Representative Director »

Nissan said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.